Renal Cell Carcinoma: A Flourishing Landscape

Sandy Srinivas, MD


January 25, 2022

While reflecting on an episode involving an assertive patient, Sandy Srinivas, MD, appraises the increasingly multifaceted landscape of renal cell carcinoma therapy, from the relatively sparse scene of a decade ago in which only a handful of tyrosine kinase inhibitors and one interleukin-2 inhibitor were available, to the current setting with exponentially more options, including the combinations of cabozantinib with nivolumab, axitinib with pembrolizumab, and lenvatinib with pembrolizumab.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.